251 related articles for article (PubMed ID: 2015598)
21. Deoxyuridine triphosphatase (dUTPase) expression and sensitivity to the thymidylate synthase (TS) inhibitor ZD9331.
Webley SD; Hardcastle A; Ladner RD; Jackman AL; Aherne GW
Br J Cancer; 2000 Sep; 83(6):792-9. PubMed ID: 10952785
[TBL] [Abstract][Full Text] [Related]
22. The quantitation by radioimmunoassay of 2'-deoxyuridine 5'-triphosphate in extracts of thymidylate synthase-inhibited cells.
Piall EM; Curtin NJ; Aherne GW; Harris AL; Marks V
Anal Biochem; 1989 Mar; 177(2):347-52. PubMed ID: 2729554
[TBL] [Abstract][Full Text] [Related]
23. Mechanism and pharmacological specificity of dUTPase-mediated protection from DNA damage and cytotoxicity in human tumor cells.
Parsels LA; Parsels JD; Wagner LM; Loney TL; Radany EH; Maybaum J
Cancer Chemother Pharmacol; 1998; 42(5):357-62. PubMed ID: 9771948
[TBL] [Abstract][Full Text] [Related]
24. Augmentation of 5-fluorouracil cytotoxicity in human colon cancer cells by dipyridamole.
Grem JL; Fischer PH
Cancer Res; 1985 Jul; 45(7):2967-72. PubMed ID: 4005834
[TBL] [Abstract][Full Text] [Related]
25. DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells.
Matsui SI; Arredondo MA; Wrzosek C; Rustum YM
Cancer Res; 1996 Oct; 56(20):4715-23. PubMed ID: 8840989
[TBL] [Abstract][Full Text] [Related]
26. Biochemical effects of folate-based inhibitors of thymidylate synthase in MGH-U1 cells.
Mitrovski B; Pressacco J; Mandelbaum S; Erlichman C
Cancer Chemother Pharmacol; 1994; 35(2):109-14. PubMed ID: 7987985
[TBL] [Abstract][Full Text] [Related]
27. Modulation of anti-metabolite effects. Effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB3717.
Jackman AL; Taylor GA; Calvert AH; Harrap KR
Biochem Pharmacol; 1984 Oct; 33(20):3269-75. PubMed ID: 6487375
[TBL] [Abstract][Full Text] [Related]
28. Enhanced cytotoxicity with interleukin-1 alpha and 5-fluorouracil in HCT116 colon cancer cells.
Geoffroy FJ; Allegra CJ; Sinha B; Grem JL
Oncol Res; 1994; 6(12):581-91. PubMed ID: 7787251
[TBL] [Abstract][Full Text] [Related]
29. Biochemical effects of a quinazoline inhibitor of thymidylate synthetase, N-(4-(N-(( 2-amino-4-hydroxy-6-quinazolinyl)methyl)prop-2-ynylamino) benzoyl)-L-glutamic acid (CB3717), on human lymphoblastoid cells.
Jackson RC; Jackman AL; Calvert AH
Biochem Pharmacol; 1983 Dec; 32(24):3783-90. PubMed ID: 6661252
[TBL] [Abstract][Full Text] [Related]
30. Enhancement of 5-fluoro-2'-deoxyuridine antineoplastic activity by 5-benzyloxybenzyloxybenzylacyclouridine in a human colon carcinoma cell line.
Chu E; Chu MY; Darnowski JW; Chen ZH; Pan BC; Chu SH
Cancer Res; 1992 Apr; 52(7):1729-36. PubMed ID: 1532344
[TBL] [Abstract][Full Text] [Related]
31. Serine/threonine protein phosphatase inhibition enhances the effect of thymidylate synthase inhibition.
Sakoff JA; Howitt IJ; Ackland SP; McCluskey A
Cancer Chemother Pharmacol; 2004 Mar; 53(3):225-32. PubMed ID: 14648018
[TBL] [Abstract][Full Text] [Related]
32. The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583).
Jackman AL; Newell DR; Gibson W; Jodrell DI; Taylor GA; Bishop JA; Hughes LR; Calvert AH
Biochem Pharmacol; 1991 Oct; 42(10):1885-95. PubMed ID: 1741766
[TBL] [Abstract][Full Text] [Related]
33. Synergistic growth inhibition of rat hepatoma cells exposed in vitro to N10-propargyl-5,8-dideazafolate with methotrexate or the lipophilic antifolates trimetrexate or metoprine.
Galivan J; Nimec Z; Rhee M
Cancer Res; 1987 Oct; 47(20):5256-60. PubMed ID: 2958130
[TBL] [Abstract][Full Text] [Related]
34. Dipyridamole potentiates adriamycin cytotoxicity by a mechanism other than inhibiting nucleoside uptake.
Kusumoto H; Maehara Y; Anai H; Kumashiro R; Sugimachi K
Anticancer Res; 1991; 11(4):1539-42. PubMed ID: 1746911
[TBL] [Abstract][Full Text] [Related]
35. In vitro synergism between 5-fluorouracil and natural beta interferon in human colon carcinoma cells.
Guglielmi A; Aschele C; Mori A; Baldo C; Russo P; Debernardis D; Valenti M; Bruno S; Taverna M; Rosso R
Clin Cancer Res; 1995 Nov; 1(11):1337-44. PubMed ID: 9815929
[TBL] [Abstract][Full Text] [Related]
36. Augmentation of 1-beta-D-arabinofuranosylcytosine cytotoxicity in human tumor cells by inhibiting drug efflux.
Chan TC
Cancer Res; 1989 May; 49(10):2656-60. PubMed ID: 2713849
[TBL] [Abstract][Full Text] [Related]
37. Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitro.
Marshman E; Newell DR; Calvert AH; Dickinson AM; Patel HR; Campbell FC; Curtin NJ
Clin Cancer Res; 1998 Nov; 4(11):2895-902. PubMed ID: 9829758
[TBL] [Abstract][Full Text] [Related]
38. Role of substrate depletion in the inhibition of thymidylate biosynthesis by the dihydrofolate reductase inhibitor trimetrexate in cultured hepatoma cells.
Rhee MS; Balinska M; Bunni M; Priest DG; Maley GF; Maley F; Galivan J
Cancer Res; 1990 Jul; 50(13):3979-84. PubMed ID: 2162250
[TBL] [Abstract][Full Text] [Related]
39. Quantitation of folic acid enhancement of antifolate synergism.
Gaumont Y; Kisliuk RL; Parsons JC; Greco WR
Cancer Res; 1992 Apr; 52(8):2228-35. PubMed ID: 1532766
[TBL] [Abstract][Full Text] [Related]
40. In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity.
Smith PG; Thomas HD; Barlow HC; Griffin RJ; Golding BT; Calvert AH; Newell DR; Curtin NJ
Clin Cancer Res; 2001 Jul; 7(7):2105-13. PubMed ID: 11448930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
